Oral News and Research

RSS

UofL associate professor to create an emergency countermeasure staffing plan

Building on the success of Louisville's response to the 2009 H1N1 influenza pandemic, Ruth Carrico, PhD, plans to use a $250,000 one-year cooperative agreement from the Centers for Disease Control and Prevention (CDC) to create an emergency countermeasure staffing plan that utilizes nursing, pharmacy and public health students.

13 Oct 2011

Study explores link between BPA exposure and breast cancer

Chronic low-level exposure to a compound found in a variety of plastic household items could pose a threat to women who overproduce a protein linked with breast cancer, say researchers at University of Alabama at Birmingham.

13 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

Teenage condom use on the rise: CDC report

A federal survey revealed by the Centers for Disease Control and Prevention (CDC) on Wednesday shows that sexually active teenagers are using condoms more often, but inconsistently.

13 Oct 2011

USPTO issues patent to Oragenics' In Vivo Induced Antigen Technology

Florida-based nutraceutical company, Oragenics, Inc., announced today the issuance of patent number 8,034,571 from the United States Patent and Trademark office for In Vivo Induced Antigen Technology.

13 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses

The National Institutes of Health (NIH) has awarded United Therapeutics Corporation a contract for up to $45 million over five years "to help develop a potential oral treatment for viruses like influenza and the mosquito-borne tropical fever dengue," the Associated Press/Washington Post reports.

12 Oct 2011

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex Pharmaceuticals, Inc. today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

Four-gene signature may predict patients at higher risk of OSCC recurrence

Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence.

11 Oct 2011

Coalition calls for affordable and flexible essential health benefits package

The newly-formed Essential Health Benefits Coalition today urged the Department of Health and Human Services (HHS) to hold the cost and affordability of the essential health benefits package paramount as recommended by the Institute of Medicine (IOM).

7 Oct 2011

Teriflunomide drug reduces relapse rate of people with MS

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

7 Oct 2011

Poor dental care leads to health problems, costs

Meanwhile, a survey finds that Americans are open to new options for dental care to help address the high costs and shortage issues.

7 Oct 2011

Viewpoints: Jobs and 'Obamacare;' jurisdictional barriers to health law challenges; reforming provider payment

By most of the usual measures, President Obama has no business being reelected. Here's why he might be anyway. On Wednesday morning, as Senate Democratic leaders were scrambling to find a way to enact part of Obama's jobs bill, a dozen Republican lawmakers assembled outside the Capitol to complain about ... health-care reform.

7 Oct 2011

Hormonal contraceptive shots and risk of HIV in African women

A new study from Africa reveals that using a hormone shot given every three months - the most popular contraceptive for women in eastern and southern Africa, may make it easier for HIV to spread between heterosexual sex partners.

5 Oct 2011

HPV may be responsible for the alarming numbers of oral cancers: Study

Sore throat for a very long time could be an early precursor of a sexually transmitted virus that is fueling a rise in oral cancer suggest researchers. Between 1988 and 2004, head, neck and throat cancers that tested positive for the human papilloma virus rose an astounding 225 percent, according to a new study.

4 Oct 2011

New NIH grant to continue exploration of Fusobacterium nucleatum-associated Beta-Defensin Inducer

Research from Case Western Reserve University School of Dental Medicine to study an isolated agent from common oral bacteria may hold the answer as to how human beta defensins (HBDs)-nature's way of keeping oral microbes from entering the body and wreaking havoc with our health-can be used to create new treatments to block bacteria from entering through the epithelial linings on and in the body.

4 Oct 2011

Dramatic rise in U.S. incidence of oropharyngeal cancer can be attributed to HPV infection

A new study of oropharyngeal cancer suggests that dramatic increases in U.S. incidence of the cancer and survival since 1984 can be attributed to infection with the human papillomavirus.

4 Oct 2011

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.

4 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

Oral News and Research

UofL associate professor to create an emergency countermeasure staffing plan

Study explores link between BPA exposure and breast cancer

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

Teenage condom use on the rise: CDC report

USPTO issues patent to Oragenics' In Vivo Induced Antigen Technology

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Four-gene signature may predict patients at higher risk of OSCC recurrence

Coalition calls for affordable and flexible essential health benefits package

Teriflunomide drug reduces relapse rate of people with MS

Poor dental care leads to health problems, costs

Viewpoints: Jobs and 'Obamacare;' jurisdictional barriers to health law challenges; reforming provider payment

Hormonal contraceptive shots and risk of HIV in African women

HPV may be responsible for the alarming numbers of oral cancers: Study

New NIH grant to continue exploration of Fusobacterium nucleatum-associated Beta-Defensin Inducer

Dramatic rise in U.S. incidence of oropharyngeal cancer can be attributed to HPV infection

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News